Edap Tms Sa (NASDAQ:EDAP) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Tuesday. The brokerage presently has a $3.25 target price on the stock. Zacks Investment Research’s target price would indicate a potential upside of 14.04% from the stock’s current price.

According to Zacks, “EDAP TMS S.A. develops, produces, markets and distributes minimally invasive medical devices, primarily for the treatment of urological diseases. They currently produce and market devices for treatment of benign prostate hyperplasia and urinary tract stones. They are also developing a third range of products for minimally invasive destruction of certain types of tumors. “

A number of other analysts have also recently commented on EDAP. HC Wainwright reaffirmed a “buy” rating on shares of Edap Tms Sa in a research note on Tuesday, August 30th. TheStreet raised Edap Tms Sa from a “sell” rating to a “hold” rating in a research note on Tuesday, September 27th.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/11/zacks-investment-research-upgrades-edap-tms-sa-edap-to-buy.html

Edap Tms Sa (NASDAQ:EDAP) traded up 4.78% during trading on Tuesday, hitting $2.85. 112,415 shares of the stock were exchanged. The firm’s 50 day moving average price is $2.92 and its 200-day moving average price is $3.26. Edap Tms Sa has a 1-year low of $2.43 and a 1-year high of $6.57. The stock has a market cap of $81.87 million, a price-to-earnings ratio of 17.38 and a beta of 1.12.

Edap Tms Sa (NASDAQ:EDAP) last announced its quarterly earnings results on Thursday, August 25th. The company reported $0.09 EPS for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.12. Edap Tms Sa had a return on equity of 58.61% and a net margin of 11.53%. On average, analysts anticipate that Edap Tms Sa will post $0.16 EPS for the current year.

A hedge fund recently bought a new stake in Edap Tms Sa stock. Perkins Capital Management Inc. acquired a new stake in shares of Edap Tms Sa (NASDAQ:EDAP) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 118,000 shares of the company’s stock, valued at approximately $391,000. Perkins Capital Management Inc. owned about 0.46% of Edap Tms Sa at the end of the most recent quarter. Institutional investors and hedge funds own 12.11% of the company’s stock.

About Edap Tms Sa

EDAP TMS SA (EDAP) is a holding company engaged in developing and marketing the Ablatherm and Focal One devices. The Company operates two divisions: High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS) (including lithotripsy activities). The Company is developing HIFU technology for the treatment of certain other types of tumors.

5 Day Chart for NASDAQ:EDAP

Get a free copy of the Zacks research report on Edap Tms Sa (EDAP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Edap Tms Sa Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edap Tms Sa and related companies with MarketBeat.com's FREE daily email newsletter.